Raptor has focused its efforts on speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. The company is primarily dedicated to underserved patient populations where they can have the greatest potential impact.
Raptor is developing a balanced, robust pipeline of drug candidates. The company’s current product portfolio includes candidates from their proprietary drug targeting platforms and in-licensed and acquired product candidates. Raptor’s current pipeline includes 5 clinical development programs plus 3 preclinical programs, all of which are based on a strong IP position.
The company is developing drug-targeting platforms based on the proprietary use of the human protein called receptor-associated protein (RAP) and the mesoderm development protein (Mesd). They believe that these proteins may have therapeutic applications in cancer, infectious diseases and neurodegenerative diseases, among others.
Raptor’s growth strategy is based on leveraging the company’s in-house research and development capabilities through partnerships, acquisitions and collaborations. This approach has already proven effective for the company, leading the way to a balanced portfolio of product candidates with the potential to reach a broad array of underserved patient populations.
Let us hear your thoughts: Raptor Pharmaceuticals Corp. Message Board